ImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Consensus PT from Analysts

Shares of ImageneBio, Inc. (NASDAQ:IMA) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $29.00.

Several equities research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of ImageneBio in a research note on Friday, August 21st. They set a “buy” rating and a $28.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th.

ImageneBio Stock Down 1.6%

Shares of IMA opened at $4.81 on Tuesday. ImageneBio has a fifty-two week low of $3.94 and a fifty-two week high of $9.10. The company’s fifty day moving average is $5.45 and its two-hundred day moving average is $5.60. The firm has a market cap of $54.59 million, a PE ratio of -1.05 and a beta of 0.70.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.27. As a group, equities research analysts anticipate that ImageneBio will post -3.23 earnings per share for the current year.

Institutional Trading of ImageneBio

Hedge funds have recently made changes to their positions in the company. Blue Owl Capital Holdings LP purchased a new position in shares of ImageneBio in the second quarter valued at $5,414,000. Monashee Investment Management LLC purchased a new stake in ImageneBio during the 4th quarter worth $632,000. Trails Edge Capital Partners LP acquired a new position in ImageneBio in the 2nd quarter worth $1,663,824. Cable Car Capital LP acquired a new position in ImageneBio in the 2nd quarter worth $4,611,000. Finally, BlackRock Inc. purchased a new stake in shares of ImageneBio during the second quarter worth about $797,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio is a biotechnology company focused on precision oncology and the development of blood-based tools for cancer research and clinical care. The company’s work centers on analyzing tumor-derived genetic material found in blood, with the goal of providing noninvasive information about a patient’s cancer.

Its technology is designed to support tumor profiling, biomarker identification, and the monitoring of disease over time. By combining molecular analysis with computational methods, ImageneBio aims to help physicians and researchers characterize tumors, identify potentially relevant treatment options, and evaluate changes in tumor biology.

Publicly available information about ImageneBio’s commercial portfolio, geographic operations, and leadership is limited.